| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
28,964 |
18,246 |
$1.37M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
13,514 |
9,243 |
$1.19M |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
5,388 |
4,637 |
$491K |
| 90882 |
|
2,066 |
1,639 |
$78K |
| 99404 |
|
233 |
233 |
$40K |
| 90836 |
|
454 |
422 |
$28K |
| 90834 |
Psychotherapy, 45 minutes with patient |
92 |
92 |
$9K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
149 |
139 |
$9K |
| 99205 |
Prolong outpt/office vis |
29 |
29 |
$5K |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
51 |
32 |
$2K |
| 90833 |
Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) |
13 |
13 |
$454.35 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
123 |
106 |
$0.00 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
250 |
217 |
$0.00 |
| M1034 |
Adults who have at least 180 days of continuous pharmacotherapy with a medication prescribed for oud without a gap of more than seven days |
170 |
132 |
$0.00 |
| G9906 |
Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) |
220 |
189 |
$0.00 |
| G8950 |
Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented |
47 |
44 |
$0.00 |
| M1171 |
Patient received at least one td vaccine or one tdap vaccine between nine years prior to the encounter and the end of the measurement period |
223 |
192 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
304 |
287 |
$0.00 |
| G8783 |
Normal blood pressure reading documented, follow-up not required |
203 |
191 |
$0.00 |
| M1168 |
Patient received an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period |
29 |
27 |
$0.00 |